Could a single month of treatment revolutionize care for atrial fibrillation patients after stenting? New research suggests a surprising answer, but it’s not without controversy. Here’s what you need to know: Patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) often face a delicate balance between preventing blood clots and managing bleeding risks. Traditionally, a year-long regimen of dual antithrombotic therapy—combining a direct oral anticoagulant (DOAC) and a P2Y12 inhibitor—has been the standard. But what if just one month of this treatment could be equally effective while significantly reducing bleeding risks? That’s the provocative finding of the OPTIMA-AF trial, presented at the American Heart Association (AHA) 2025 Scientific Sessions in New Orleans. But here’s where it gets controversial: While the trial shows promising results, some experts argue the data isn’t conclusive enough to change clinical practice just yet. Let’s dive in.
The OPTIMA-AF trial, conducted across 75 sites in Japan, enrolled 1,088 patients (mean age 75, 79% men) with AF and coronary artery disease (CAD) who required PCI. Participants were randomized to either one month of dual therapy followed by DOAC monotherapy or a full year of dual therapy. The primary goal? To determine if a shorter treatment duration could maintain efficacy while minimizing bleeding risks. The results were eye-opening: the rate of death or thromboembolic events at one year was 5.4% in the short-duration group versus 4.5% in the year-long group—a difference that fell within the noninferiority margin of 5% (P = 0.002). More strikingly, major or clinically relevant nonmajor bleeding, the primary safety endpoint, was nearly halved in the short-duration group (4.8% vs. 9.5%; P = 0.004).
And this is the part most people miss: While the findings seem compelling, the trial had a lower-than-expected event rate, which complicates interpretation. Electrophysiologist Sana Al-Khatib, MD, from the Duke Clinical Research Institute, noted that while the results are reassuring, they may not be generalizable to all populations, particularly since the trial primarily included East Asian patients, who have distinct stroke and bleeding risk profiles. ‘I personally won’t change my practice based on these results,’ she said, ‘but I’d love to see more diverse, adequately powered trials to confirm these findings.’
The trial’s design is worth noting: patients received a Xience everolimus-eluting stent during PCI, with most procedures guided by intracoronary imaging. The most common DOAC used was edoxaban, and clopidogrel or prasugrel served as the P2Y12 inhibitor. Aspirin was added in about 5% of cases, at the discretion of treating physicians. The primary efficacy endpoint—a composite of all-cause death, myocardial infarction, stent thrombosis, stroke, or systemic embolism—showed no significant difference between groups. However, the shorter therapy duration demonstrated superiority in reducing bleeding risks.
Here’s the controversial question: Should these findings prompt a shift in clinical guidelines, or do we need more data? Manesh Patel, MD, president-elect of the AHA, pointed out that while the trial’s noninferiority margin aligned with the observed event rate, the numerical increase in all-cause deaths with shorter therapy (4.1% vs. 3.0%) raises concerns. He also highlighted that the bleeding reduction was primarily driven by nonmajor bleeds, with no significant difference in major bleeding events. Current U.S. guidelines already recommend DOACs over vitamin K antagonists in AF patients post-PCI, with early aspirin discontinuation to limit bleeding. But could a one-month dual therapy strategy become the new norm?
For now, Patel suggests a nuanced approach: while dual therapy will likely remain standard for AF patients with acute coronary syndrome (ACS) undergoing PCI, de-escalation strategies—such as one to three months of dual therapy—may be considered for those without ACS, depending on bleeding risks. What do you think? Is one month enough, or do we need more evidence? Share your thoughts in the comments—this debate is far from over.
